Exact Mass: 498.2213
Exact Mass Matches: 498.2213
Found 500 metabolites which its exact mass value is equals to given mass value 498.2213
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Moexipril
Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Vincosamide
Vincosamide is a monoterpenoid indole alkaloid. Vincosamide is a natural product found in Camptotheca acuminata, Sinoadina racemosa, and other organisms with data available. Strictosamide has important effects on inflammation and inflammatory pain. Strictosamide possesses antiplasmodial and antifungal activities[1]. Strictosamide has important effects on inflammation and inflammatory pain. Strictosamide possesses antiplasmodial and antifungal activities[1]. Vincosamide, an alkaloid from Psychotria leiocarpa extract, inhibits the acetylcholinesterase (AChE) activity with anti-inflammatory activity[1]. Vincosamide, an alkaloid from Psychotria leiocarpa extract, inhibits the acetylcholinesterase (AChE) activity with anti-inflammatory activity[1].
Conivaptan
Conivaptan is only found in individuals that have used or taken this drug. It is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).Conivaptan is a dual AVP antagonist with nanomolar affinity for human arginine vasopressin V1A and V2 receptors in vitro. This antagonism occurs in the renal collecting ducts, resulting in aquaresis, or excretion of free water. C - Cardiovascular system > C03 - Diuretics > C03X - Other diuretics > C03XA - Vasopressin antagonists C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist D045283 - Natriuretic Agents > D065092 - Antidiuretic Hormone Receptor Antagonists D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents
N2-Maltulosylarginine
N2-Maltulosylarginine is found in tea. N2-Maltulosylarginine is a constituent of Korean red ginseng. Constituent of Korean red ginseng. N2-Maltulosylarginine is found in tea.
Apitolisib
Masitinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, PDB, Protein Data Bank C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
2-[2-[(1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
beta-Alanine, N-(N-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2-oxo-1-(phenylmethyl)ethyl)-L-phenylalanyl)-
Sograzepide
Tyr-Gly-Gly-Phe-Gly-NH2
Vincosamide
Avapritinib
Tigloylgomisin O
Tigloylgomisin O is a natural product found in Schisandra sphenanthera with data available. See also: Schisandra chinensis fruit (part of).
Mallotophilippen A
A chromenol that is 2H-chromene-5,7-diol substituted by geminal methyl groups at position 2, a 2-methylbutanoyl group at position 8 and a 2,4,6-trihydroxy-3-methyl-5-(2-methylpropanoyl)benzyl group at position 6. Isolated from Mallotus philippensis, it exhibits anti-inflammatory activity.
1,2-Dihydro-5,9,10-trihydroxy-7-(3-hydroxy-3-methylbutyl)-2-(1-hydroxy-1-methylethyl)-8-(3-methyl-2-butenyl)-6H-furo[2,3-c]xanthen-6-one
1-(3-Furyl)-4b,7,7,9b,11a-pentamethyl-3,8-dioxohexadecahydrooxireno[2,3-d]oxireno[2,3:7,8]naphtho[2,1-f]isochromen-5-yl acetate #
(5R)-5-[(1S,2S,3R,4R)-3-[(4E)-hex-4-enoyl]-6-[(2E,4E)-hexa-2,4-dienoyl]-5,7-dihydroxy-4,7-dimethyl-8-oxobicyclo[2.2.2]oct-5-en-2-yl]-4-hydroxy-3,5-dimethyl-2,5-dihydrofuran-2-one
Drummondin F
A benzenetriol that is a derivative of filicinic acid. Isolated from the stems and leaves of Hypericum drummondii, it exhibits antibacterial activity against Gram-positive bacteria Staphylococcus aureus and Bacillus subtilis and the acid fast bacterium Mycobacterium smegmatis.
5,9,10-trihydroxy-7-(3-hydroxy-3-methylbutyl)-2-(1-hydroxy-1-methylethyl)-8-(3-methylbut-2-en-1-yl)-1,2-dihydro-6H-furo[2,3-c]xanthen-6-one
7alpha-acetylobacunol|7alpha-obacunyl acetate|proceranone
punaglandin 4
15-keto Fluprostenol isopropyl ester
Val Glu His Asp
6-Acetylnimbandiol
6-acetylnimbandiol is a limonoid found in Azadirachta indica. It has a role as a plant metabolite. It is an acetate ester, a cyclic terpene ketone, an enone, a member of furans, a limonoid, a tetracyclic triterpenoid and a methyl ester. 6-Acetylnimbandiol is a natural product found in Azadirachta indica with data available. A limonoid found in Azadirachta indica.
Strictosamide
Strictosamide is a member of beta-carbolines. Strictosamide is a natural product found in Amsonia orientalis, Ophiorrhiza pumila, and other organisms with data available. D000970 - Antineoplastic Agents > D014748 - Vinca Alkaloids Annotation level-3 Strictosamide has important effects on inflammation and inflammatory pain. Strictosamide possesses antiplasmodial and antifungal activities[1]. Strictosamide has important effects on inflammation and inflammatory pain. Strictosamide possesses antiplasmodial and antifungal activities[1].
2USP2X4F50
Angeloylgomisin O is a natural product found in Schisandra chinensis with data available. See also: Schisandra chinensis fruit (part of).
Heteroclitin C
Deacetylnimbin
6-deacetylnimbin is a limonoid that is nimbin in which the acetyloxy group at position 6 is replaced by a hydroxy hroup. It has been isolated from Azadirachta indica. It has a role as a plant metabolite, an antifeedant and an insect growth regulator. It is a cyclic terpene ketone, an enone, a member of furans, a limonoid, a tetracyclic triterpenoid, a methyl ester and a diester. It is functionally related to a nimbin. 6-Deacetylnimbin is a natural product found in Azadirachta indica and Aristolochia indica with data available. A limonoid that is nimbin in which the acetyloxy group at position 6 is replaced by a hydroxy hroup. It has been isolated from Azadirachta indica.
C28H34O8_Methyl (2R,3aR,4aS,5R,6R,9aR,10S,10aR)-2-(3-furyl)-5-hydroxy-10-(2-methoxy-2-oxoethyl)-1,6,9a,10a-tetramethyl-9-oxo-3,3a,4a,5,5a,6,9,9a,10,10a-decahydro-2H-cyclopenta[b]naphtho[2,3-d]furan-6-carboxylate
C28H34O8_(2E,4E)-1-{(1R,3S,7S,8R,10S)-12-[(4E)-4-Hexenoyl]-1,6,8,13-tetrahydroxy-3,7,10,14-tetramethyl-2,9-dioxapentacyclo[8.4.0.0~3,8~.0~4,14~.0~7,11~]tetradeca-5,12-dien-5-yl}-2,4-hexadien-1-one
C28H34O8_2(5H)-Furanone, 5-[(1S,2S,3R,4R,7S)-5,7-dihydroxy-4,7-dimethyl-8-oxo-6-[(2E,4E)-1-oxo-2,4-hexadien-1-yl]-3-[(4E)-1-oxo-4-hexen-1-yl]bicyclo[2.2.2]oct-5-en-2-yl]-4-hydroxy-3,5-dimethyl-, (5R)
C26H30N2O8_Oxayohimban-21-one, 19,20-didehydro-16-ethenyl-17-(beta-D-glucopyranosyloxy)-, (16alpha)
(1R,19R,20S)-19-ethenyl-18-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4(9),5,7,15-pentaen-14-one
(19R)-19-ethenyl-18-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4(9),5,7,15-pentaen-14-one
(5R)-5-[(1S,2S,3R,4R)-3-[(4E)-hex-4-enoyl]-6-[(2E,4E)-hexa-2,4-dienoyl]-5,7-dihydroxy-4,7-dimethyl-8-oxobicyclo[2.2.2]oct-5-en-2-yl]-4-hydroxy-3,5-dimethyl-2,5-dihydrofuran-2-one_major
Ala Asp Phe Phe
Ala Phe Asp Phe
Ala Phe Phe Asp
Cys Ile Thr Tyr
Cys Ile Tyr Thr
Cys Leu Thr Tyr
Cys Leu Tyr Thr
Cys Thr Ile Tyr
Cys Thr Leu Tyr
Cys Thr Tyr Ile
Cys Thr Tyr Leu
Cys Tyr Ile Thr
Cys Tyr Leu Thr
Cys Tyr Thr Ile
Cys Tyr Thr Leu
Asp Ala Phe Phe
Asp Asp His Ile
Asp Asp His Leu
Asp Asp Ile His
Asp Asp Leu His
Asp Glu His Val
Asp Glu Val His
Asp Phe Ala Phe
Asp Phe Phe Ala
Asp His Asp Ile
Asp His Asp Leu
Asp His Glu Val
Asp His Ile Asp
Asp His Leu Asp
Asp His Val Glu
Asp Ile Asp His
Asp Ile His Asp
Asp Leu Asp His
Asp Leu His Asp
Asp Val Glu His
Asp Val His Glu
Glu Asp His Val
Glu Asp Val His
Glu Phe Phe Gly
Glu Phe Gly Phe
Glu Gly Phe Phe
Glu His Asp Val
Glu His Ile Thr
Glu His Leu Thr
Glu His Thr Ile
Glu His Thr Leu
Glu His Val Asp
Glu Ile His Thr
Glu Ile Thr His
Glu Leu His Thr
Glu Leu Thr His
Glu Thr His Ile
Glu Thr His Leu
Glu Thr Ile His
Glu Thr Leu His
Glu Val Asp His
Glu Val His Asp
Phe Ala Asp Phe
Phe Ala Phe Asp
Phe Asp Ala Phe
Phe Asp Phe Ala
Phe Glu Phe Gly
Phe Glu Gly Phe
Phe Phe Ala Asp
Phe Phe Asp Ala
Phe Phe Glu Gly
Phe Phe Gly Glu
Phe Gly Glu Phe
Phe Gly Phe Glu
Phe Met Thr Thr
Phe Thr Met Thr
Phe Thr Thr Met
Gly Glu Phe Phe
Gly Phe Glu Phe
Gly Phe Phe Glu
Gly Pro Tyr Tyr
Gly Tyr Pro Tyr
Gly Tyr Tyr Pro
His Asp Asp Ile
His Asp Asp Leu
His Asp Glu Val
His Asp Ile Asp
His Asp Leu Asp
His Asp Val Glu
His Glu Asp Val
His Glu Ile Thr
His Glu Leu Thr
His Glu Thr Ile
His Glu Thr Leu
His Glu Val Asp
His Ile Asp Asp
His Ile Glu Thr
His Ile Thr Glu
His Leu Asp Asp
His Leu Glu Thr
His Leu Thr Glu
His Asn Gln Thr
His Asn Thr Gln
His Gln Asn Thr
His Gln Gln Ser
His Gln Ser Gln
His Gln Thr Asn
His Ser Gln Gln
His Thr Glu Ile
His Thr Glu Leu
His Thr Leu Glu
His Thr Asn Gln
His Thr Gln Asn
His Val Asp Glu
His Val Glu Asp
Ile Cys Thr Tyr
Ile Cys Tyr Thr
Ile Asp Asp His
Ile Asp His Asp
Ile His Asp Asp
Ile Thr Cys Tyr
Ile Thr Tyr Cys
Ile Tyr Cys Thr
Ile Tyr Thr Cys
Leu Cys Thr Tyr
Leu Cys Tyr Thr
Leu Asp Asp His
Leu Asp His Asp
Leu His Asp Asp
Leu Thr Cys Tyr
Leu Thr Tyr Cys
Leu Tyr Cys Thr
Leu Tyr Thr Cys
Met Phe Thr Thr
Met Ser Val Tyr
Met Ser Tyr Val
Met Thr Phe Thr
Met Thr Thr Phe
Met Val Ser Tyr
Met Val Tyr Ser
Met Tyr Ser Val
Met Tyr Val Ser
Asn His Gln Thr
Asn His Thr Gln
Asn Gln His Thr
Asn Gln Thr His
Asn Thr His Gln
Asn Thr Gln His
Pro Gly Tyr Tyr
Pro Tyr Gly Tyr
Pro Tyr Tyr Gly
Gln His Asn Thr
Gln His Gln Ser
Gln His Ser Gln
Gln His Thr Asn
Gln Asn His Thr
Gln Asn Thr His
Gln Gln His Ser
Gln Gln Ser His
Gln Ser His Gln
Gln Ser Gln His
Gln Thr His Asn
Gln Thr Asn His
Ser His Gln Gln
Ser Met Val Tyr
Ser Met Tyr Val
Ser Gln His Gln
Ser Gln Gln His
Ser Val Met Tyr
Ser Val Tyr Met
Ser Tyr Met Val
Ser Tyr Val Met
Thr Cys Ile Tyr
Thr Cys Leu Tyr
Thr Cys Tyr Ile
Thr Cys Tyr Leu
Thr Glu Ile His
Thr Phe Met Thr
Thr Phe Thr Met
Thr His Asn Gln
Thr His Gln Asn
Thr Ile Cys Tyr
Thr Ile Tyr Cys
Thr Leu Cys Tyr
Thr Leu His Glu
Thr Leu Tyr Cys
Thr Met Phe Thr
Thr Met Thr Phe
Thr Asn His Gln
Thr Asn Gln His
Thr Gln His Asn
Thr Gln Asn His
Thr Thr Phe Met
Thr Thr Met Phe
Thr Tyr Cys Ile
Thr Tyr Cys Leu
Thr Tyr Ile Cys
Thr Tyr Leu Cys
Val Asp Glu His
Val Asp His Glu
Val Glu Asp His
Val His Asp Glu
Val His Glu Asp
Val Met Ser Tyr
Val Met Tyr Ser
Val Ser Met Tyr
Val Ser Tyr Met
Val Tyr Met Ser
Val Tyr Ser Met
Tyr Cys Ile Thr
Tyr Cys Leu Thr
Tyr Cys Thr Ile
Tyr Cys Thr Leu
Tyr Gly Pro Tyr
Tyr Gly Tyr Pro
Tyr Ile Cys Thr
Tyr Ile Thr Cys
Tyr Leu Cys Thr
Tyr Leu Thr Cys
Tyr Met Ser Val
Tyr Met Val Ser
Tyr Pro Gly Tyr
Tyr Pro Tyr Gly
Tyr Ser Met Val
Tyr Ser Val Met
Tyr Thr Cys Ile
Tyr Thr Cys Leu
Tyr Thr Ile Cys
Tyr Thr Leu Cys
Tyr Val Met Ser
Tyr Val Ser Met
Tyr Tyr Gly Pro
Tyr Tyr Pro Gly
7Z-punaglandin 4
punaglandin 5
9-keto Fluprostenol isopropyl ester
Conivaptan
C - Cardiovascular system > C03 - Diuretics > C03X - Other diuretics > C03XA - Vasopressin antagonists C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist D045283 - Natriuretic Agents > D065092 - Antidiuretic Hormone Receptor Antagonists D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents
UK II
2-O-(beta-D-galactopyranosyl-(1->6)-beta-D-galactopyranosyl) 2S-hydroxynonanoic acid
Dihydrotrichotetronine
punaglandin 4
punaglandin 5
N-(2-Diethylaminoethyl)-α,2-dimethyl-1,3-benzodioxole-2-acetamide
Apitolisib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2) inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with a?Ki?of 17 nM for mTOR. Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2) inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with a?Ki?of 17 nM for mTOR.
4-[[5,7-dihydroxy-2,2-dimethyl-8-(2-methylpropanoyl)chromen-6-yl]methy l]-3,5-dihydroxy-6,6-dimethyl-2-(2-methylpropanoyl)cyclohexa-2,4-dien- 1-one
Sograzepide
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent C308 - Immunotherapeutic Agent > C63817 - Chemokine Receptor Antagonist Sograzepide?(Netazepide; YF 476; YM-220) is an extremely?potent?, highly?selective?and orally active Gastrin/CCK-B antagonist with an IC50 value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC50 of 502 nM[1]. Sograzepide?(Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human?Gastrin/CCK-B receptors, with Ki values of 0.068, 0.62 and 0.19 nM, respectively[2].
15-Keto Travoprost
Avapritinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
Olorofim
D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent
Gdc-0152
C274 - Antineoplastic Agent > C129839 - Apoptotic Pathway-targeting Antineoplastic Agent
Sotrastaurin acetate
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor
CCK-B Receptor Antagonist 1
(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor, and has the potential of reducing the secretion of gastric acid.
drummondin E
A member of the class of resorcinols that is a derivative of filicinic acid. Isolated from the stems and leaves of Hypericum drummondii, it exhibits antibacterial activity against Gram-positive bacteria Staphylococcus aureus and Bacillus subtilis and the acid fast bacterium Mycobacterium smegmatis.
12-(3,4-Dimethoxy-phenyl)-10-(2-morpholin-4-yl-ethyl)-10,12-dihydro-7-oxa-8,10-diaza-benzo[a]anthra cen-11-ylideneamine
Masitinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, PDB, Protein Data Bank C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
2-Butanoyl-4-[(8-butanoyl-5,7-dihydroxy-2,2-dimethylchromen-6-yl)methyl]-3,5-dihydroxy-6,6-dimethylcyclohexa-2,4-dien-1-one
validamycin A(1+)
An ammonium ion resulting from the protonation of the amino group of validamycin A. The major species at pH 7.3.
2-[5-(2-fluorophenyl)-2-tetrazolyl]-N-[2-oxo-2-[(phenylmethyl)amino]ethyl]-N-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
(2R,6Z)-2-Benzyl-1-(cyclopropanecarbonyl)-4-[(4-fluorophenyl)methyl]-5-(4-methoxyphenyl)-5,8-dihydro-2H-1,4-diazocin-3-one
4-hydroxy-1-(2-methylpropyl)-2-oxo-N-[4-oxo-2-(phenylmethyl)-3-quinazolinyl]-5,6,7,8-tetrahydroquinoline-3-carboxamide
3-[[1-[1-(2-furanylmethyl)-5-tetrazolyl]propyl-(2-phenylethyl)amino]methyl]-7-methoxy-1H-quinolin-2-one
3-(4-nitrophenyl)-N-(4-phenylbutyl)-5-(phenylmethyl)-4,6-dihydro-3aH-pyrrolo[3,4-d]isoxazole-6a-carboxamide
(1R)-2-acetyl-N-(2,4-difluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(2S,3S,3aR,9bR)-1-[cyclopropyl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-7-phenyl-N-(2-pyridin-4-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-methylbenzenesulfonamide
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-methylbenzenesulfonamide
N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-methylbenzenesulfonamide
2-[(3S,6aR,8S,10aR)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
2-[(3S,6aR,8R,10aR)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
(2R,3R,3aS,9bS)-1-[cyclopropyl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-7-phenyl-N-(2-pyridin-4-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
2-[(3R,6aR,8S,10aR)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
2-[(3R,6aS,8S,10aS)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
2-[(3S,6aS,8S,10aS)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
2-[(3S,6aS,8R,10aS)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
(1S,9R,10R,11R)-N-(2,3-dihydro-1H-inden-2-yl)-10-(hydroxymethyl)-6-oxo-12-propanoyl-5-pyridin-4-yl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
1-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
1-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
1-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
1-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
(1R,9S,10S,11S)-N-(2,3-dihydro-1H-inden-2-yl)-10-(hydroxymethyl)-6-oxo-12-propanoyl-5-pyridin-4-yl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylbenzamide
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-methylbenzenesulfonamide
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-methylbenzenesulfonamide
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-methylbenzenesulfonamide
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-methylbenzenesulfonamide
1-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
1-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
1-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
1-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
2-[(3R,6aR,8R,10aR)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
2-[(3R,6aS,8R,10aS)-1-(4-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
(1R,9S,10S,11S)-10-(hydroxymethyl)-6-oxo-5-[(E)-2-phenylethenyl]-N-propyl-12-(pyridine-4-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1S,9R,10R,11R)-10-(hydroxymethyl)-6-oxo-5-[(E)-2-phenylethenyl]-N-propyl-12-(pyridine-4-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1S)-2-acetyl-N-(2,4-difluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
4-[[4-(1-benzothiophen-2-yl)pyrimidin-2-yl]amino]-N-(4-pyrrolidin-1-ylpiperidin-1-yl)benzamide
(1R,19R,20S)-19-ethenyl-18-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,15-pentaen-14-one
(1-butanoyloxy-3-phosphonooxypropan-2-yl) (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
(1-acetyloxy-3-phosphonooxypropan-2-yl) (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
Moexipril
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
1-[4-[[2-(2-Amino-5-pyrimidinyl)-7-methyl-4-(4-morpholinyl)-6-thieno[3,2-d]pyrimidinyl]methyl]-1-piperazinyl]-2-hydroxy-1-propanone
Mutant IDH1-IN-1
Mutant IDH1-IN-1 is a mutant-selective IDH1 inhibitor with with IC50s of 4, 42, 80 and 143 nM against mutant IDH1 R132C/R132C, IDH1 R132H/R132H, IDH1 R132H/WT and wild type IDH1, respectively.
(1s,20s)-19-ethenyl-18-{[(2s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15-pentaen-14-one
(8r,9s,10s)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2,4,6,13,18-hexaen-8-yl (2e)-2-methylbut-2-enoate
1,5-dimethyl 3-[1-(furan-3-yl)-2',5',7a-trimethyl-3,4'-dioxo-6,7-dihydro-1h-spiro[cyclopenta[c]pyran-5,1'-cyclopentan]-2'-en-5'-yl]-2,2-dimethylpentanedioate
(1s,2s,3s,4s,7s,8z,11r,12s,13r,16r,17s)-2-(acetyloxy)-3,4,12,16,17-pentahydroxy-4,9,13,17-tetramethyl-5-oxo-6-oxatricyclo[11.4.0.0³,⁷]heptadeca-8,14-dien-11-yl acetate
methyl (5s,6s)-5,6-bis(acetyloxy)-7-[(1e,2r)-4-chloro-2-hydroxy-2-(oct-2-en-1-yl)-5-oxocyclopent-3-en-1-ylidene]heptanoate
(1r,4s,9s,10r,12s,17r)-9,10,15-trihydroxy-16-(1-hydroxyhexa-2,4-dien-1-ylidene)-1,9,12,14-tetramethyl-4-(prop-1-en-1-yl)-3,11-dioxatetracyclo[8.7.0.0²,⁷.0¹²,¹⁷]heptadeca-2(7),14-diene-6,13-dione
(1r,2r,6s,7r,9s)-6,7,12-trihydroxy-4,13-bis[(2e,4e)-1-hydroxyhexa-2,4-dien-1-ylidene]-2,6,9,11-tetramethyl-8-oxatricyclo[7.4.0.0²,⁷]tridec-11-ene-3,10-dione
(1s,2r,4s,7s,8s,11r,12r,18s,20r)-7-(furan-3-yl)-1,8,12,17,17-pentamethyl-5,15-dioxo-3,6,16-trioxapentacyclo[9.9.0.0²,⁴.0²,⁸.0¹²,¹⁸]icos-13-en-20-yl acetate
(9r,10r,11r)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(19),2(7),3,5,12,14(18)-hexaen-11-yl (2z)-2-methylbut-2-enoate
(2r,4as,8s,8ar)-8-{[(6,8-dimethoxy-2-oxochromen-7-yl)oxy]methyl}-4,4,8a-trimethyl-7-methylidene-3-oxo-hexahydronaphthalen-2-yl acetate
(9s,10s,11s)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(19),2(7),3,5,12,14(18)-hexaen-11-yl (2e)-2-methylbut-2-enoate
(1r,4s,5z,7r,8s)-7-[(4e)-hex-4-enoyl]-3-hydroxy-8-[(2s)-3-hydroxy-2,4-dimethyl-5-oxofuran-2-yl]-5-[(2e,4e)-1-hydroxyhexa-2,4-dien-1-ylidene]-1,3-dimethylbicyclo[2.2.2]octane-2,6-dione
3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2,4,6,13,18-hexaen-8-yl 2-methylbut-2-enoate
7-(hex-4-enoyl)-3-hydroxy-8-(3-hydroxy-2,4-dimethyl-5-oxofuran-2-yl)-5-(1-hydroxyhexa-2,4-dien-1-ylidene)-1,3-dimethylbicyclo[2.2.2]octane-2,6-dione
5,6,12,14-tetrahydroxy-13-[(2e)-7-hydroxy-3,7-dimethyloct-2-en-1-yl]-7-(3-methylbut-2-en-1-yl)-2,9-dioxatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3(8),4,6,12,14-hexaen-10-one
(2r)-3-[(2r,3s,4r)-2-[(s)-(1s)-cyclohex-2-en-1-yl(hydroxy)methyl]-4-hexyl-3,5-dihydroxy-3-methyl-4h-pyrrole-2-carbonylsulfanyl]-2-[(1-hydroxyethylidene)amino]propanoic acid
(18s,19r,20s)-19-ethenyl-18-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15-pentaen-14-one
7alpha-acetylobacunol
{"Ingredient_id": "HBIN013036","Ingredient_name": "7alpha-acetylobacunol","Alias": "NA","Ingredient_formula": "C28H34O8","Ingredient_Smile": "CC(=O)OC1CC2C(OC(=O)C=CC2(C3C1(C45C(O4)C(=O)OC(C5(CC3)C)C6=COC=C6)C)C)(C)C","Ingredient_weight": "498.6 g/mol","OB_score": "36.07530404","CAS_id": "NA","SymMap_id": "SMIT07911","TCMID_id": "NA","TCMSP_id": "MOL006262","TCM_ID_id": "NA","PubChem_id": "57390140","DrugBank_id": "NA"}
Argininyl-fructosyl-glucose
{"Ingredient_id": "HBIN016722","Ingredient_name": "Argininyl-fructosyl-glucose","Alias": "argininyl-fructosyl-glucose","Ingredient_formula": "C18H34N4O12","Ingredient_Smile": "C1C(C(C(C(O1)(CNC(CCCN=C(N)N)C(=O)O)O)O)OC2C(C(C(C(O2)CO)O)O)O)O","Ingredient_weight": "498.56","OB_score": "0.740573214","CAS_id": "NA","SymMap_id": "SMIT01073","TCMID_id": "1674","TCMSP_id": "MOL005311","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}